Momenta Pharmaceuticals

J&J to buy Momenta Pharmaceuticals for $6.5B

The drugmaker emphasized the full global rights it would acquire to Momenta's lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.

By Alaric DeArment

BioPharma, Pharma

Momenta’s biosimilars pullback could portend further industry exits

Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.

By Alaric DeArment

Redefining Payer Operations: Data-Driven Strategies for the Future of Healthcare

This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.

By Veradigm

The Top Appointment Scheduling Software for Wellness Clinics

Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.

By PatientNow

Simplify Salon & Spa Employee Management with Meevo’s Comprehensive Software

Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.

By Meevo